Is TSHA or TVTX more undervalued in 2026?

CirclFi compares Taysha Gene Therapies, Inc. (TSHA) and Travere Therapeutics, Inc. (TVTX) using 13 institutional-grade valuation models. TSHA has a Quality of Company score of 6.0/10 while TVTX scores 6.3/10.

Which is a better buy — TSHA or TVTX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do TSHA and TVTX valuations compare?

TSHA at $5.92 and TVTX at $47.76 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

TSHA vs TVTX Valuation Comparison 2026 — Intrinsic Value Analysis

TSHA

Biotechnology

Taysha Gene Therapies, Inc.

Quality

6.0

out of 10

Value Trap

SAFE

Price

$5.92

Last close

Models

9/13

Active

TVTX

Biotechnology

Travere Therapeutics, Inc.

Quality

6.3

out of 10

Value Trap

SAFE

Price

$47.76

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	TSHA Fair Value	TSHA Upside	TVTX Fair Value	TVTX Upside
Bayesian DCF	Intrinsic	$2.02	-65.8%	$12.78	-73.2%
Earnings Power Value	Intrinsic	—	—	$13.84	-68.6%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$1.05	-82.3%	—	—
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for TSHA vs TVTX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

TSHA vs TVTX — Which Stock Is More Undervalued?

TVTX scores higher with a 6.3/10 quality rating vs TSHA's 6.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Taysha Gene Therapies, Inc. (TSHA) and Travere Therapeutics, Inc. (TVTX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

TSHA currently trades at $5.92 with a QOC of 6.0/10, while TVTX trades at $47.76 with a QOC of 6.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).